Mineralys Therapeutics, Inc. MLYS Investments and Cash
Investments and Cash at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentsAndCash.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s investments and cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s investments and cash?
- Mineralys Therapeutics, Inc. (MLYS) reported investments and cash of $646.1M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s investments and cash changed year-over-year?
- Mineralys Therapeutics, Inc.'s investments and cash increased by 88.4% year-over-year, from $343M to $646.1M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s investments and cash?
- Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s investments and cash has grown at a 65.7% compound annual growth rate (CAGR), from $239M to $656.6M.
- What does investments and cash mean?
- This includes cash, cash equivalents, and investment securities that are restricted or intended for use beyond the next twelve months. It provides insight into the company's long-term capital reserves available to fund multi-year clinical development programs.